Summary
Intravenous cibenzoline was evaluated in 37 patients with acute supraventricular tachyarrhytymias and a ventricular rate >120 beats/min. The presenting arrhythmia was atrial fibrillation in 15 patients, atrial flutter in 5, ectopic atrial tachycardia in 11, and paroxysmal atrioventricular (AV) junctional reentrant tachycardia in 6 patients. Intravenous cibenzoline was administered as a bolus given over 2 minutes, at a dose of 1 mg/kg in the first 26 patients and 1.2 mg/kg in the subsequent 11 patients, 15 minutes following failure of placebo (isotonic glucose). The results were evaluated 15 minutes after the intravenous injection. Restoration of sinus rhythm was obtained in 3 out of 6 patients with paroxysmal AV junctional tachycardia (50%) and in 7 out of 31 patients (23%) with atrial tachyarrhythmias (5 out of 15 patients with atrial fibrillation and 2 out of 16 patients with ectopic atrial tachycardia or atrial flutter). Five additional patients with atrial tachyarrhythmias had slowing of ventricular rate below 100 beats/min. Therefore, a satisfactory result, that is, restoration of sinus rhythm or slowing of ventricular rate, occurred in 15 patients (40.5%). Side effects were transient, including visual disturbance (one patient), asymptomatic widening of QRS complex (three patients), incessant reciprocating tachycardia (one patient), and acceleration of ventricular rate (eight patients), resulting in 1:1 flutter, with poor tolerance in two patients. In conclusion, intravenous cibenzoline may be useful in selected patients with supraventricular tachyarrhythmias. Careful monitoring is recommended during therapy in view of the possible occurrence of 1:1 atrial flutter.
Similar content being viewed by others
References
Millar JS, Vaughan-Williams EM. Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new anti-arrhythmic drug cibenzoline which protects against action potential shortening in hypoxia.Br J Pharmacol 1982;75:469–478.
Kushner M, Magiros E, Peters R, Carliner N, Plotnick G, Fischer M. The electrophysiologic effects of oral cibenzoline.J Electrocardiol 1984;17:15–24.
Touboul P, Atallah G, Kirkorian G, et al. The electrophysiologic effects of cibenzoline in humans related to dose and plasma concentration.Am Heart J 1986;112:333–339.
Browne KF, Prystowsky EN, Zipes DP, Chilson DA, Heger JJ. Clinical efficacy and electrophysiologic effects of cibenzoline therapy in patients with ventricular arrhythmias.J Am Coll Cardiol 1984;3:857–864.
Kostis JB, Krieger S, Moreyra A, Cosgrove N. Cibenzoline for treatment of ventricular arrhythmias: A double-blind placebo-controlled study.J Am Coll Cardiol 1984;4:372–377.
Miura DS, Keren G, Torres V, Butler B, Aogaichi A, Somberg JC. Antiarrhythmic effects of cibenzoline.Am Heart J 1985;109:827–833.
Klein RC, Horwitz LD, Rushforth N. Efficacy and safety of oral cibenzoline for ventricular arrhythmias.Am J Cardiol 1986;57:592–597.
Rothbart ST, Saksena S. Clinical electrophysiology, efficacy and safety of chronic oral cibenzoline therapy in refractory ventricular tachycardia.Am J Cardiol 1986;57:941–946.
Seals AA, Haider R, Leon C, et al. Antiarrhythmic efficacy and hemodynamic effects of cibenzoline in patients with non-sustained ventricular tachycardia and left ventricular dysfunction.Circulation 1987;75:800–808.
Desoutter P, Duffour A, Aymard MF, Haiat R. Etude pharmacocinétique d'un nouvel antiarythmique, la cibenzoline, à la phase aigüe d'un infarctus myocardique. Corrélations thérapeutiques.Thérapie 1983;38:327–245.
Pfitzner P, Manz M, Luderitz B. Cibenzolin: Electrophysiologische Wirkungen bei Wolff-Parkinson-White Syndrom und AV-Knoten-Reentrytachykardie.Zeitschr Kardiol 1988;77(Suppl 1):39.
Waleffe A, Duffour A, Aymard MF, Kulbertus H. Electrophysiologic effects and antiarrhythmic activity and pharmacokinetics of cibenzoline studied with programmed stimulation of the heart in patients with supraventricular reentrant tachycardias.Eur Heart J 1985;6:253–260.
Hackman MR, Lo Lee T, Brooks MA. Determination of cibenzoline in plasma and urine by high-performance liquid chromatography.J Chromatogr 1983;273:347–356.
Lévy S. Effects électrophysiologiques des antiarythmiques. Leur valeur prédictive des effets thérapeutiques.Arch Mal Coeur 1981;74:29–35.
Goy JJ, Greie M, Hurni M, Finci L, Duc J, Sigwart J. Conversion of supraventricular arrhythmias to sinus rhythm using flecainide.Eur Heart J 1985;6:518–524.
Metz D, Chapoutot L, Chabert JP, et al. Cibenzoline IV versus flécaïnide IV dans la réduction des fibrillations auricularies spontanées d'installation récente.L'information Cardiologique 1990;14:413–416.
Gursoy S, Atie J, Steurer G, Willems H, Andries E, Brugada P. Electrophysiologic effects of intravenous cibenzoline in idiopathic atrial flutter in man.Eur Heart J 1991;337(abstr. P1743).
Haiat R, Aymard MF, Dufour A. La cibenzoline intraveineuse dans le traitement des troubles du rythme supraven-triculaires et ventriculaires.Arch Mal Coeur 1985;spécial edition:95–97.
Lacombe P, Cointe R, Metge M, Bru P, Gerard R, Lévy S. Intravenous flecainide in the management of acute supraventricular tachyarrhythmias.J Electrophysiol 1982;2:19–22.
Robertson CE, Miller HC. Extreme tachycardia complicating the use of disopyramide in atrial flutter.Br Heart J 1980;44:602–603.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bru, P., Cointe, R., Paganelli, F. et al. Intravenous cibenzoline in the management of acute supraventricular tachyarrhythmias. Cardiovasc Drug Ther 9, 85–88 (1995). https://doi.org/10.1007/BF00877748
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00877748